Summaries for patients. Treatment of venous thromboembolism: recommendations from the American College of Physicians and the American Academy of Family Physicians.
D000553:Ambulatory Care; D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005260:Female; D006493:Heparin / Q000191:economics / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D019934:International Normalized Ratio; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000517:prevention & control / Q000628:therapy; D011655:Pulmonary Embolism / Q000150:complications / Q000517:prevention & control / Q000628:therapy; D055502:Secondary Prevention; D053828:Stockings, Compression; D013923:Thromboembolism / Q000150:complications / Q000517:prevention & control / Q000628:therapy*; D015912:Thrombolytic Therapy; D016306:Vena Cava Filters; D020246:Venous Thrombosis / Q000150:complications / Q000517:prevention & control / Q000628:therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014812:Vitamin K; D006493:Heparin